Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells

Weiguo Zhang1, Vivian R. Ruvolo1, Chen Gao1, Liran Zhou1, William Bornmann3, Twee Tsao1, Wendy D. Schober1, Paul Smith4, Sylvie Guichard4, Marina Konopleva1,2, and Michael Andreeff1,2

Abstract

Aberrant activation of multiple signaling pathways is common in acute myelogenous leukemia (AML) cells, which can be linked to a poor prognosis for patients with this disease. Previous research with mTOR or MEK inhibitors revealed cytostatic, rather than cytotoxic, effects in \emph{in vitro} and \emph{in vivo} AML models. We evaluated the combination effect of the mTOR inhibitor AZD8055 and the MEK inhibitor selumetinib on human AML cell lines and primary AML samples. This combination demonstrated synergistic proapoptotic effects in AML cells with high basal activation of MEK and mTOR. We next incorporated the BH3 mimetic ABT-737 into this combination regimen to block Bcl-2, which further enhanced the apoptogenic effect of MEK/mTOR inhibition. The combination treatment also had a striking proapoptotic effect in CD33⁺/CD34⁺ AML progenitor cells from primary AML samples with NRAS mutations. Mechanistically, upregulation of the proapoptotic protein Bim, accompanied by the downregulation of the antiapoptotic protein Mcl-1 (mainly via protein degradation), seemed to play critical roles in enhancing the combination drug effect. Furthermore, the modulation of survivin, Bax, Puma, and X-chromosome-linked inhibitor of apoptosis protein (XIAP) expression suggested a role for mitochondria-mediated apoptosis in the cytotoxicity of the drug combination. Consequently, the concomitant blockade of prosurvival MEK/mTOR signaling and the deactivation of Bcl-2 could provide a mechanism-based integrated therapeutic strategy for the eradication of AML cells. Mol Cancer Ther; 13(7); 1848–59. ©2014 AACR.

Introduction

Aberrant gene expression/signaling pathways like the RAS/Raf/MEK/ERK and the PI3K/Akt/mTOR pathways can promote tumorigenesis in many tissues, including the hematopoietic system. Indeed, the deregulation of RAS/Raf/MEK/ERK or PI3K/Akt/mTOR signaling has been shown to contribute to leukemogenesis (1–3), and the NRAS-activating mutations, which abnormally stimulate RAF/MEK/ERK and PI3K/Akt/mTOR signaling, are found in a third of hematopoietic malignances, including acute myelogenous leukemia (AML; ref. 1). Furthermore, we have previously reported that the simultaneous activation of the aforementioned signaling pathways is consistently associated with poor disease prognosis in patients with AML (4).

In several studies by our group and others, the MEK inhibitors CI1040 and selumetinib (also known as AZD6244) exerted mainly cytostatic effects in \emph{in vitro} and \emph{in vivo} AML models. This was also the case for the mTOR inhibitors CCI779 and RAD001 (5–7). Thus, interrupting one of these signaling pathways independently seems to be insufficient to trigger cell death in AML cells (5, 8, 9).

The B-cell lymphoma 2 (Bcl-2) family of proteins are key regulators of cancer cell apoptosis. The antiapoptotic Bcl-2 proteins Bcl-2, Bcl-xL, and myeloid cell leukemia sequence 1 (Mcl-1) prevent cellular apoptosis via their expression and dimerization with the proapoptotic Bcl-2 proteins Bim and Bax. The overexpression of the antiapoptotic Bcl-2 proteins correlates with an overall lower overall survival rates for patients with AML (10, 11). Several small-molecule Bcl-2 inhibitors have been developed, and they have shown encouraging single-agent activity in preclinical and clinical trials (12, 13). We hypothesize that the concomitant blockade of the MAPK and mTOR signaling, in conjunction with interference with antiapoptotic Bcl-2 family members, could promote marked cytotoxic activity in AML cells, including AML stem cells. The purpose of this study was to determine...
if, and by what mechanisms, the cosuppression of MEK and mTOR signaling in concert with the interruption of antiapoptotic Bcl-2 family members could effectively induce apoptosis in AML cells. We examined a three-drug combination consisting of the mTOR inhibitor AZD8055, the MEK inhibitor selumetinib, and the antiapoptotic Bcl-2 family mimetic ABT-737 on human AML cells and primary AML samples. This combination demonstrated marked proapoptotic effects in AML cells with high basal activation of MEK and mTOR. The rationale for this combination treatment was based on (i) the ability to disable Mcl-1–mediated resistance associated with the inhibition of pERK, (ii) overcoming resistance to MEK inhibition mediated by constitutive and reactive PI3K/AKT in AML cells (12, 14), and (iii) by mediating loss of inhibition mediated by constitutive and reactive PI3K/AKT in AML cells (12, 14), and (iii) by mediating loss of mitochondrial inner transmembrane potential in the presence of Bcl-2 antagonist ABT-737. Our results suggest that this drug combination can be potentially effective in eradicating AML cells, and, as such, could be an important strategy for controlling AML in vivo.

Materials and Methods

Reagents and antibodies

Selumetinib (also known as AZD6244 and ARRY-142886) and AZD8055 were provided by AstraZeneca. ABT-737 was synthesized at the University of Texas MD Anderson Cancer Center based on its published chemical structure (15). The chemical structures of the above-mentioned reagents are shown in Supplementary Fig. S1. Antibodies against human phosphorylated (p)-p44/42 MAPK (ERK1/2) (Thr202/Tyr204), p-AKT(Ser473), p-AKT(Thr308), p-S6K(Ser240/244), p-Rb(Thr790), p-4E-BP1 (Thr37/46), p-Bad (Ser136), p-MEK1/2 were purchased from Cell Signaling Technology, as were the antibodies against AKT, S6K, 4E-BP1, Bad, Bid, Bcl-xL, survivin, caspase-8, caspase-9, and cleaved caspase-3. Antibodies against Bax, Mcl-1, X-chromosome-linked inhibitor of apoptosis protein (XIAP), and p27Kip-1 were purchased from BD Biosciences; antibody against Bcl-2 was purchased from Dako; antibody against Bak was purchased from Upstate; antibodies against ERK2, Cdk2, and Cdk4 were purchased from Santa Cruz Biotechnology; and antibodies against Bim, cyclin D1, Cdc2, and Puma were purchased from CalBiochem.

AML cell lines and patient samples

The human AML cell lines U937, KG-1, and MV4-11 were obtained from the ATCC. The OCI/AML3 cell line was kindly provided by Dr. M. Minden (Princess Margaret Hospital, Toronto, Ontario, Canada). The MOLM13 cell line was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen. U937, KG-1, MOLM13, and OCI/AML3 cells were validated in September 2010 by short tandem repeat DNA fingerprinting using the AmpFISTR Identifier Kit according to the manufacturer’s instructions (Applied Biosystems). Genetic characteristics of AML cell lines used in this study are summarized in Supplementary Table S1.

Peripheral blood and bone marrow samples were obtained from patients with newly diagnosed, relapsed, or refractory AML after written informed consent had been obtained from each patient according to institutional guidelines of the University of Texas MD Anderson Cancer Center. All cells, including those obtained from peripheral blood and bone marrow samples, were cultured in RPMI 1640 culture medium supplemented with 10% fetal calf serum.

Cell viability and apoptosis assays

Cell viability was assessed using an automated cell counter employing the Trypan blue dye exclusion method, and cell apoptosis was examined by flow cytometry as described previously (16). To evaluate apoptosis induction by treatment with AZD8055 plus selumetinib in 2 sets of peripheral blood and bone marrow samples (with and without NRAS mutations), mononuclear cells were separated by Ficoll–Hypaque density-gradient centrifugation (Sigma Chemicals). Apoptosis of bulk leukemic and leukemic progenitor cells (i.e., gating the AML cells with CD34+ or CD33+) was determined as described above. Induction of specific apoptosis was calculated using the following formula: specific apoptosis (%) = 100 (drug-induced apoptosis – spontaneous apoptosis)/(100 – spontaneous apoptosis) (see ref. 17).

Cell proliferation assay

AML cells were treated with the indicated agent for 24 hours, and bromodeoxyuridine (BrdUrd; BD Pharmingen) was added to the medium at the last 45 minutes of treatment to allow BrdUrd incorporation into newly synthesized cellular DNA. The cells were harvested and fixed in 70% cold ethanol, and BrdUrd was labeled with an anti–BrdUrd–fluorescein isothiocyanate antibody and measured using flow cytometry (18).

Immunoblot analysis

AML cells were treated with AZD8055, selumetinib, or ABT-737 alone or in combination as indicated and then collected for analysis. Semiquantitative immunoblotting data were generated using the Scion imaging software program (Beta version 4.03; Scion; ref. 18).

For the immunoprecipitation studies, AML cells were lysed and the cell lysates (containing ~0.5 mg of total protein in each sample) were incubated overnight with a primary anti–Bcl-2 antibody. Protein A/G PLUS-agarose (Santa Cruz Biotechnology) was added to the lysis buffer for an additional 4 hours of incubation at 4°C. Bcl-2 family proteins were resolved using SDS–PAGE. The amount of Bax bound to Bcl-2 was determined using the following formula: specific apoptosis (%) = 100 (drug-induced apoptosis – spontaneous apoptosis)/(100 – spontaneous apoptosis) (see ref. 17).

Knockdown of Bim or Mcl-1 protein

Bim protein was knocked down by transfecting siRNAs (sequence: 5'-GACCAGAGAGGUAGACAAUUGdTdT-
3') and mock control siRNAs (Dharmacon RNAi Technologies) into OCI/AML3 and U937 leukemia cells using an electroporation method (T-solution, X-001 and C-solution, W-001, respectively; Amaxa Biosystems) following the manufacturer's instructions. The final concentration of siRNA in the electroporation buffer was 200 nM/L.

Mcl-1 protein was knocked down by lentiviral transfection with a gene-specific shRNA transfer vector targeting residues 2421–2440 on RefSeq NM_021960.4. Lentivirus was prepared by cotransfection of HEK293T cells (ATCC) with an equal molar mix of transfer vector and packaging plasmids (psPAX2 and pMD2.G; plasmids 12260 and 12259, respectively, from Addgene) using JetPrime transfection reagent as directed in the manufacturer’s instructions (Polyplus). The OCI/AML3 cells underwent lentivirus transfection with Mcl-1 shRNA vector or nonspecific control vector (pLKO.1 TRC control, plasmid 10879; Addgene) and selected with puromycin (Invitrogen) starting at 0.5 µg/mL. Knockdown was verified by immunoblot analysis and real-time PCR.

Real-time PCR assays
The OCI/AML3 and MOLM13 cells were treated with the indicated drugs for 6 hours, and total RNA was extracted with Trizol (Life Technologies) following the manufacturer’s protocol. cDNA was synthesized as described previously (19), and duplicated TaqMan gene expression assays were carried out in a 25-µL reaction containing the cDNA equivalent of 1.0 ng of total RNA with TaqMan gene expression assays (Life Technologies) for Mcl-1 (Hs03043899_m1), Bim (Hs00708019_s1), or housekeeping gene18S (Hs03928985_g1) using an ABI model 7900HT fast real-time PCR system. Data were analyzed by the ∆∆Ct method using RQ Manager 1.2.1 software (Life Technologies), and the relative abundance of target in treated cells, normalized to that of vehicle treated cells, is reported as follows: RQ = 2 exp [−(∆∆Ct)], where ∆∆Ct = ∆Ctreated − ∆Ctvehicle, and ∆Ct = Ct_gene of interest − Ct_18S.

Establishment of NRAS-mutated leukemia cells
A plasmid harboring the NRAS cDNA (IMAGE:3826638; Open Biosystems) was used as a template to generate the NRAS open reading frame (ORF) flanked by Nhel (5') and XhoI (3') sites by PCR with HiFi Hot Start polymerase (Kapa Biosystems) and the primers TGTGAAACTGG (forward) and GCTAGCCGCCATGACTGAGTACAAA (reverse). Lentiviral transfer vectors were then constructed by inserting the wild-type or mutant G12D into the Nhel and NotI sites of pCDH-CMV-MSC-EF1-Puro (System Biosciences). The vectors were introduced into MV4-11 cells by lentiviral transduction as described (20). Positive cells were selected and maintained with puromycin (up to 1 µg/mL). NRAS activation was confirmed by measuring the phosphorylation level of MEK by immunoblotting.

Mitochondrial inner transmembrane potential (∆ψm) analysis
MV4-11-NRAS-wild type and MV4-11-NRAS-mutated cells were treated with AZD8055, selumetinib, or ABT-737 alone or in combination as indicated for 24 hours and then collected for staining with CMXRos (300 nM/L) and MitoTracker Green (100 µM/L; both from Molecular Probes) for 1 hour at 37°C. The ∆ψm was determined using flow cytometry by measuring CMXRos retention (red fluorescence) while simultaneously adjusting for the mitochondrial mass (green fluorescence as described previously; ref. 21).

Statistical analyses
The Student t test was used to analyze immunoblot, cell growth, and apoptosis data. P values ≤ 0.05 were considered statistically significant. The Chou–Talalay method (22) was used to determine combination indices for the agents. A combination index value of 1 indicated an additive effect, <1 synergism, and >1 antagonism. The mean combination index values were calculated at different effect levels (50%, 75%, and 90% effective concentrations). All statistical tests were two-sided, and the results are expressed as the mean ± SD (error bars) of triplicate samples.

Results
Cotargeting of signaling pathways with AZD8055 and selumetinib enhanced the growth-inhibitory effect of either agent alone in AML cells
Targeted treatment with MEK inhibitor selumetinib or the allosteric mTOR inhibitors CCI779 or RAD001 had only limited effects in most leukemia cell lines in our previous studies (6, 7). Therefore, for the current study, we assessed the effect of combining selumetinib with the novel mTOR kinase inhibitor AZD8055 in AML cell lines. Synergistic effects on cell growth inhibition were observed with OCI/AML3, U937, or MOLM13 (Fig. 1A, Supplementary Fig. S2). AML cells that displayed synergistic effects in response to the combination treatment expressed relatively high levels of p-ERK and p-AKT (Fig. 1B). However, KG-1 cells lack detectable p-ERK and p-AKT and showed an antagonistic effect. Furthermore, the combination treatment notably suppressed the levels of ERK1/2 (Thr202/Tyr204) and...
AKT (Ser473) phosphorylation in the OCI/AML3, MOLM13, and U937 cells, but had no consistent effect on the phosphorylation of AKT Thr308 (Fig. 1C).

We next measured BrdUrd incorporation by flow cytometry to determine whether the combination treatment affected cell-cycle progression. In all lines, cell-cycle progression was modestly impaired by the single and combination agent treatments as there were fewer cells in S-phase of the cell cycle compared with the controls (Fig. 1D). Although KG-1 cells lack detectable p-AKT and express only trace levels of p-ERK, approximately 50% of these cells were apparently blocked from entering S-phase by mTOR or combined inhibition compared with controls (Fig. 1D).

The KG-1 cells expressed p-S6K (Ser240/244), which was markedly suppressed by the combination treatment (Fig. 1C), suggesting that S6 protein may be critical in the G1–S-phase transition of the cell cycle. Interestingly, the expression of p-S6K, which is best known as a downstream target of PI3K/mTOR/AKT signaling rather than as a target of one of the MEK/ERK signaling cascades, decreased significantly when MEK signaling was suppressed by selumetinib only in OCI/AML3 and U937 cells, but not in MOLM13 or KG-1 cells.

Figure 1. Dual blockade of mTOR/MEK signaling synergistically or additively inhibits growth in AML lines OCI/AML3, MOLM13, and U937, but not KG-1. A, AML cells were treated with AZD8055, selumetinib, or both at the indicated concentrations for 48 hours. Inhibition of cell growth was measured using viable cell counts as described in Materials and Methods, and expressed as the percentage of untreated cells. Data, the mean of four independent determinations. Error bars, 95% CIs. **: P < 0.01; and ***: P < 0.001. B, basal expression levels of phosphorylated and total ERK, AKT, and Bcl-2 proteins was determined by immunoblotting. Numbers indicate ratio of phosphorylated proteins to the respective total proteins. C, AML cells were treated with AZD8055 and selumetinib at the indicated concentrations for 24 hours, and the profile of signaling and cell-cycle-related checkpoint proteins was measured by immunoblotting. α-tubulin was used as loading control. D, AML cells were treated with the indicated agents for 24 hours, and BrdUrd incorporation was determined using flow cytometry after labeling with anti-BrdUrd-fluorescein isothiocyanate antibody. Data, the mean of triplicate experiments.
In contrast, the phosphorylation of eukaryotic initiation factor 4E-binding protein (4E-BP1), a downstream protein activated by mTORC1/S6K signaling (23), was inhibited by AZD8055 but not selumetinib in all four cell lines (Fig. 1C). Upregulation of the cell-cycle inhibitor p27Kip-1 and downregulation of the G1 phase–related checkpoint protein cyclin D1/cdk4 complexes were observed in all tested AML cell lines. However, downregulation of cdk2, cdc2, and p-Rb was generally observed in OCI/AML3, MOLM13, and U937 cells, but not in KG-1 cells, suggesting that these proteins may be not specific to the G1–S-phase transition of the cell cycle.

Blockade of mTOR/MEK signaling has synergistic cytotoxic effects that are associated with modulation of proapoptotic Bim and antiapoptotic Mcl-1 proteins

The AZD8055 and selumetinib agent combination produced synergistic proapoptotic effects in OCI/AML3, MOLM13, and U937 cells (Fig. 2A). In addition, in OCI/AML3, MOLM13, and U937 cells, the proapoptotic protein Bim was upregulated, and the antiapoptotic proteins Mcl-1, p-Bad(Ser136), and survivin were downregulated by AZD8055 and even more so by the combination with selumetinib (Fig. 2B). We also observed modulated expression of the p53-regulated proteins...
Puma and Bad in certain leukemia cell lines. However, no notable changes in the expression of Bcl-2, Bcl-xL, or Bax were observed. Of note, the upregulation of Bim expression and downregulation of Mcl-1 expression correlated with cleavage of caspase-3, implying that Bim and Mcl-1 play important roles in apoptosis induction. This combination was seemingly antagonistic in the KG-1 cells (Fig. 2A), which have a low basal level of ERK and AKT activation, and did not affect Mcl-1 expression in these cells (Fig. 2B).

We therefore suspected that the modulation of Mcl-1 and Bim levels might play a key role in the combination treatment–induced apoptosis. Further investigation of the mRNA transcription level showed that the combination upregulated Bim only in MOLM13, but not in OCI/AML3 cells. No statistically significant modulation was observed in Mcl-1 levels (Fig. 2C). We next treated OCI/AML3 cells in the presence of the protein translation inhibitor cycloheximide, which further induced apoptosis in the treatment groups (Fig. 2D). Cycloheximide treatment moderately decreased protein levels of Bim, but not of Mcl-1 after 6-hour exposure. (Fig. 2D, inset). On the other hand, suppression of protein degradation with proteasome inhibitors bortezomib or MG132 did not markedly influence the combination-induced cell apoptosis (Supplementary Fig. S3). Taken together, the combination-induced changes of Mcl-1 and Bim protein levels might result from translational, rather than transcriptional or proteasomal degradation, effects.

To further evaluate the roles of Bim and Mcl-1 in apoptosis induction, we silenced Bim expression with siRNA and Mcl-1 expression with shRNA and assessed apoptosis induction after treatment with AZD8055 and selumetinib for 48 hours. The knockdown of Bim markedly reversed the combination effect of apoptosis induction by the treatment with AZD8055 and selumetinib in OCI/AML3 (Fig. 3A) and U937 (Supplementary Fig. S4) cells, whereas the knockdown of Mcl-1 enhanced this effect in OCI/AML3 cells (Fig. 3B). These results suggested that Bim and Mcl-1 play opposite roles in apoptosis induction by this combination treatment in the AML cells.

### Interference with Bcl-2 protein dimerization enhanced apoptotic effects induced by combined AZD8055 and selumetinib in AML cells

Because the induction of apoptosis in leukemia cells is largely controlled by dimerization of proapoptotic and antiapoptotic proteins (11), we hypothesized that, in addition to the inhibition of mTOR/MEK signaling, the inhibition of binding of Bax or Bim with their respective partners, Bcl-2 and Bcl-xL, would further enhance apoptosis induction. We, and others, have reported previously that the Bcl-2 antagonist ABT-737 can bind to Bcl-2 family members resulting in leukemic cell death (12, 24). In addition, the expression level of the antiapoptotic Mcl-1 protein is inversely correlated with cell sensitivity to ABT-737 due to the inability of the latter to bind and inhibit Mcl-1 (12, 25). We tested the three-drug combination of ABT-737, AZD8055, and selumetinib at low concentrations (0.06, 0.1, and 0.3 μmol/L, respectively), and observed significantly enhanced proapoptotic responses in KG-1, OCI/AML3, and MOLM13 cells compared with ABT-737 only or with the AZD8055/selumetinib combination only (Fig. 4A). In the U937 cells which had the lowest basal level of Bcl-2 protein of the four AML cell lines tested (Fig. 1B), this drug combination did not induce marked apoptosis (Fig. 4A). However, apoptosis induction in the U937 cells could be boosted by increasing the concentrations of AZD8055 to 0.3 μmol/L and selumetinib to 0.9 μmol/L (Fig. 4B), suggesting that at higher doses of the mTOR inhibitors were still capable of inducing apoptosis in leukemic cells possessing a high basal level of p-AKT driven by PTEN deletion. Impressively, the KG-1 cells that were resistant to selumetinib and AZD8055 (Supplementary Figs. S5 and S6) demonstrated enhanced sensitivity to the three-drug combination after a 48-hour treatment (Fig. 4A).
We treated the ABT-737–sensitive KG-1 cells and ABT-737–resistant OCI/AML3 cells with ABT-737 alone or with AZD8055/selumetinib combination to gain an insight into the mechanism of apoptosis induction by the triple-drug combination treatment. An immunoprecipitation assay pull-down of the Bcl-2 complex with anti–Bcl-2 antibody indicated that Bcl-2/Bax heterodimerization was reduced in both cell lines after a 6-hour...
ABT-737 treatment, and even more markedly so in cells treated with all the three drugs (Fig. 4C). After a 24-hour combination treatment, we observed the cleavage of caspase-9, caspase-8, caspase-3, and Bid, cytochrome c release, and the localization of Bax to the mitochondria (Fig. 4D). Furthermore, Bax was upregulated resulting in an increased Bax:Bcl-2 ratio, and the expression of Mcl-1 and the XIAP was decreased possibly because of caspase-3-mediated cleavage. These findings suggested that ABT-737 enhances the proapoptotic effect of the AZD8055/selumetinib combination by interfering with Bcl-2 function, thus triggering mitochondria-mediated cell death.

Three-drug combination treatment exerted synergistic proapoptotic effects in AML blast cells with NRAS mutations

We next tested the three-drug combination on peripheral blood or bone marrow cells obtained from patients with AML (the patient cytogenetic characteristics are summarized in Supplementary Table S2). Because RAS mutation is known to activate both the MEK and mTOR pathways, we assessed apoptosis induction in these samples based on their NRAS mutational status. Selumetinib or AZD8055 alone induced modest apoptosis in five of seven samples harboring NRAS mutations (i.e., cases 3, 4, 5, 6, and 7; Fig. 5A), and in one sample with wild-type RAS that had an FLT3-ITD mutation (i.e., case 11; Fig. 5B).

By comparison, the combination treatment with both agents enhanced apoptosis in most NRAS-mutated samples (except case 2; Fig. 5A), and in two of the seven NRAS wild-type samples (i.e., cases 11 and 13; Fig. 5B). Both of the latter cases harbored mutations of FLT3. Except for cases 1 and 3, ABT-737 was highly effective in inducing apoptosis in primary AML cells, and the combination of all three agents further induced apoptosis in bulk leukemic, as well as in CD34+/CD33+, cells in 12 of 14 patient samples. Overall, the specific apoptosis induction by the three-agent combination was higher in the CD33+/CD33−, cells in 12 of 14 patient samples. The key apoptotic and signaling proteins in isogenic-paired NRAS wild-type and NRAS-mutated AML cells MV4-11. Compared with wild-type cells, cells with mutant NRAS were considerably more sensitive to treatment with selumetinib and ABT-737, or to the three-drug combination (Fig. 6A). Immunoblotting demonstrated enhanced MAPK signaling in NRAS-mutated cells manifesting as high basal levels of p-ERK, in concert with a high expression of Mcl-1 (Fig. 6B). However, the suppression of p-ERK with selumetinib failed to markedly suppress Mcl-1, and it triggered only a modest induction of apoptosis as shown by the level of cleaved caspase-3. In turn, the combined selumetinib and AZD8055 further diminished the level of Mcl-1 in NRAS-mutant cells, and this combination paired with ABT-737 caused a marked decrease of Mcl-1 protein and triggered a discernible cleavage of caspase-3 (Fig. 6B).

Discussion

In this study, we tested the combination effects of the MEK inhibitor selumetinib and the mTOR inhibitor AZD8055 in human AML cells. Simultaneous inhibition of ERK and mTOR signaling by these agents led to an enhanced cytostatic effect in the OCI/AML3, MOLM13, and U937 cells. However, this treatment showed no synergistic effect in the KG-1 cells, which exhibit only trace basal levels of phospho-ERK and -AKT. Interestingly, we noticed that targeting MEK signaling with selumetinib drastically suppressed the p-S6K level in the OCI/AML3 and U937 cells, which was not accompanied by a decrease in the level of p-4E-BP1. The S6K and 4E-BP1 proteins are well-known mTOR substrates that contribute to cell proliferation and survival (26). S6K modulation by MAPK signaling is not well understood, although the PI3K/Akt and Ras/MAPK pathways are known to signal in a parallel manner to regulate Tsc1 and 2, and mediate the phosphorylation of S6K (27). Our data indicate that MEK/ERK signaling in conjunction with mTOR signaling plays a prominent role in regulating S6K activity in AML cells. However, the blockade of S6K activity alone is not the major predictor of cell sensitivity to MEK inhibition as exemplified by the vastly different mean half maximal inhibitory concentrations required for inhibiting the growth of OCI/AML3 cells (0.03 μmol/L; 95% confidence interval, CI, 0.01–0.08 μmol/L) and U937 cells (392 μmol/L; 95% CI, 0.5–2960 μmol/L; Supplementary Fig. S5) despite a similar suppression level of p-S6K.
Conversely, mTOR inhibition not only activated MAPK signaling, which is reportedly dependent on a feedback loop of the S6K/Pi3K/Ras pathway (14), but it also relieves the negative feedback loop, resulting in increased phosphorylation of AKT at Thr308 (28). Our findings support the notion that multiple circuitry feedback mechanisms are operational in these cells, and may also explain, at least in part, why the blockade of the AKT/mTOR/S6K axis had limited activity in phase I/II clinical trials in patients with hematologic malignancies (29).

The interaction and balance between pro- and anti-apoptotic Bcl2 family proteins dictate cell fate (30). Bim is a positive effector of apoptosis induction and is involved in mitochondria-mediated apoptosis induction (31). Our previous studies demonstrated that upregulation of Bim expression, which triggers mitochondria-mediated apoptosis, plays a critical role in the antileukemia efficacy of Raf/MEK/ERK inhibitors (32). In the present study, we showed that selumetinib, or both selumetinib and AZD8055, markedly upregulated Bim expression, and that the further addition of ABT-
ABT-737 enhanced this upregulation as well as apoptosis induction. In contrast, silencing the expression of Bim markedly diminished apoptosis induction by the agents.

The level of Mcl-1 is a predictive biomarker for sensitivity to therapy-induced apoptosis induction in a variety of hematopoietic malignancies, and its upregulation was mediated via ERK/Elk-1 or AKT/mTOR signaling (33, 34). Consistent with these reported findings, targeting of MEK or mTOR decreased Mcl-1 expression. Mcl-1 expression was further diminished in the presence of ABT-737, and resulted in enhanced apoptosis induction in AML cells. Moreover, lowering the Mcl-1 level by shRNA enhanced drug-induced apoptosis (Supplementary Fig. S7). Specifically, compared with NRAS wild-type MV4-11 cells, the NRAS-mutant MV4-11 cells expressed a higher basal level of Mcl-1 protein that was subsequently diminished by the combined targeting of MEK, mTOR, and Bcl-2 pathways to trigger apoptosis induction. Thus, the three-drug combination was much more effective against AML cells with NRAS mutations compared with those with wild-type NRAS.

The interaction of Bim with Mcl-1 interferes with the cytochrome c-releasing capability of Bim and protects cells against Bim-mediated apoptosis (35). The downregulation of Mcl-1 expression (or cleavage of Mcl-1) may lead to release of Bim from specific binding with Mcl-1 to trigger apoptosis. ERK-mediated phosphorylation of Bim EL (i.e., the extra-long spliced form of the Bim protein) promotes its proteasomal degradation (36), and phosphorylation of Mcl-1 slows this turnover (37).
Furthermore, Akt-dependent glucose metabolism and ERK/ELK-1 activation promote Mcl-1 synthesis to maintain cell survival and differentiation (38, 39). Our findings suggest that the simultaneous suppression of PI3K/mTOR signaling and interference with Bcl-2 family protein dimerization are essential for drug-induced death of AML cells with a high AKT expression. A recent study using U937 cells indicated that the combination of PI3K/mTOR inhibitors with ABT-737 abrogated Bim binding to Bcl-2/Bcl-xL, which allowed Bim to activate Bax and Bak to exert proapoptotic activity (40). Recent studies indicate that leukemia stem cells (LSC) are characterized by relatively low levels of reactive oxygen species with an aberrant overexpression of BCL-2. Interestingly, the inhibition of BCL-2 reduced oxidative phosphorylation and selectively eradicated these quiescent LSCs (41). In our study, AML cells with high p-AKT and p-ERK levels (e.g., the MV4-11-NRAS-mutated cells) were efficiently killed by the triple-drug combination. This was accompanied by loss of ΔΨm, indicating the high antileukemia potency of this treatment strategy against AML cells with gain-of-function NRAS mutations. This would also suggest a selective potency of this combination for targeting quiescent LSCs.

In summary, cotargeting the MEK and mTOR pathways may be an effective treatment strategy for patients who have AML cells that express high levels of MEK and mTOR, or in patients whose AML cells harbor NRAS mutations. This treatment may be further potentiated using the BH3 mimetic ABT-737. This three-drug combination could pave the way for the development of integrated therapeutic strategies that take advantage of the synergistic antileukemia effects, thereby leading to the design of novel, clinically viable combinations for AML therapy.

References


Disclosure of Potential Conflicts of Interest

P. Smith has ownership interest in AstraZeneca PLC. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: W. Zhang, M. Konopleva
Development of methodology: W. Zhang, W. Bornmann
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W. Zhang, V.R. Ruvolo, C. Gao, L. Zhou, W.D. Schober, M. Andreeff
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. Zhang, V.R. Ruvolo, C. Gao, M. Konopleva, M. Andreeff
Writing, review, and/or revision of the manuscript: W. Zhang, P. Smith, M. Konopleva, M. Andreeff
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V.R. Ruvolo, P. Smith
Study supervision: M. Konopleva
Other (e.g., writing assistance, technical editorial assistance): T. Tsao
Other (provision of research materials (compounds) and advice on their use): P. Smith
Other (contributed knowledge of the mTOR kinase inhibitor during critique and review of results): S. Guichard

Acknowledgments

The authors thank Wenjing Chen and Teresa McQueen who provided patient information and prepared patient samples for this study, AstraZeneca for providing selumetinib and AZD8055, and Numsen Hal, Jr. and Elizabeth L. Hess who provided critical reviews and editorial assistance to the authors during preparation of this article.

Grant Support

This work was supported in part by grants from NIH/NCI (CA143805, CA100632, CA055164, and CA049639), a Cancer Center Support Grant (CA 16722, to M. Andreeff), and a Leukemia SPORE Career Development Award (CA100632-05, to W. Zhang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 17, 2013; revised March 25, 2014; accepted April 9, 2014; published OnlineFirst April 16, 2014.
ABT-737 Enhances MEK/mTOR Inhibition-Induced AML Apoptosis


36. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004;23:5301–15.


Molecular Cancer Therapeutics

Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells

Weiguo Zhang, Vivian R. Ruvolo, Chen Gao, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-13-0576

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2014/04/17/1535-7163.MCT-13-0576.DC1

Cited articles
This article cites 41 articles, 15 of which you can access for free at:
http://mct.aacrjournals.org/content/13/7/1848.full.html#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
/content/13/7/1848.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.